Regular self-monitoring of blood glucose is crucial for proper insulin dosing and gives a reliable foundation for reasonable glycaemic control. According to recent data, recommended values for glycated haemoglobin A1c as set by the professional associations remain out of the reach for a large proportion of the paediatric population. In the last decades, the treatment of type 1 diabetes has changed significantly as new devices gain a role in routine clinical care. Real-time glucose levels can be monitored with continuous glucose monitoring (CGM), which provides a broad spectrum of information on glucose trends on a moment-to-moment basis. This information can be useful for patients' decision making and clinicians' understanding of patients' conduct. However, several barriers, including the current price, impede a broader use of CGM in most regions of the world. This review summarizes data from randomized, controlled trials that included a paediatric population, and it provides some evidence-based visions for the possible broader utilization of CGM, also for incorporation into insulin delivery devices that enable a closed-loop insulin delivery.

Keywords:
Type 1 diabetes, Continuous glucose monitoring, Hypoglycaemia, Children and adolescents
1.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
2.
Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network: The T1D Exchange Clinic Registry. J Clin Endocrinol Metab 2012;97:4383-4389.
3.
American Diabetes Association: Standards of medical care in diabetes - 2013. Diabetes Care 2014;37(suppl 1):S5-S13.
4.
Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingensmith GJ: Assessment of glycemic control and adolescents with diabetes. Pediatr Diabetes 2009;10(suppl 12):71-81.
5.
Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjornsdottir S, Eliasson B; Steering Committee of the Swedish National Diabetes Register: Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 2007;30:496-502.
6.
Rosenbauer J, Dost A, Karges B, Hungele A, Stahl A, Bachle C, Gerstl EM, Kastendieck C, Hofer SE, Holl RW; DPV Initiative and the German BMBF Competence Network Diabetes Mellitus: Improved metabolic control in children and adolescents with type 1 diabetes: a trend analysis using prospective multicenter data from Germany and Austria. Diabetes Care 2012;35:80-86.
7.
de Beaufort CE, Swift PG, Skinner CT, Aanstoot HJ, Aman J, Cameron F, Martul P, Chiarelli F, Daneman D, Danne T, Dorchy H, Hoey H, Kaprio EA, Kaufman F, Kocova M, Mortensen HB, Njølstad PR, Phillip M, Robertson KJ, Schoenle EJ, Urakami T, Vanelli M; Hvidøre Study Group on Childhood Diabetes 2005: Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? Diabetes Care 2007;30:2245-2250.
8.
Nathan DM, DCCT/EDIC Research Group: The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014;37:9-16.
9.
Dovc K, Telic SS, Lusa L, Bratanic N, Zerjav-Tansek M, Kotnik P, Stefanija MA, Battelino T, Bratina N: Improved metabolic control in pediatric patients with type 1 diabetes: a nationwide prospective 12-year time-trends analysis. Diabetes Technol Ther 2014;16:33-40.
10.
Pickup JC: Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med 2012;366:1616-1624.
11.
Klonoff DC1, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, Wolpert H; Endocrine Society: Continuous glucose monitoring: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:2968-2979.
12.
Phillip M, Danne T, Shalitin S, Buckingham B, Laffel L, Tamborlane W, Battelino T; Consensus Forum Participants: Use of continuous glucose monitoring in children and adolescents. Pediatr Diabetes 2012;13:215-228.
13.
Liebl A, Henrichs HR, Heinemann L, Freckmann G, Biermann E, Thomas A; Continuous Glucose Monitoring Working Group of the Working Group Diabetes Technology of the German Diabetes Association: Continuous glucose monitoring: evidence and consensus statement for clinical use. J Diabetes Sci Technol 2013;7:500-519.
14.
Heinemann L, DeVries JH: Evidence for continuous glucose monitoring: sufficient for reimbursement? Diabet Med 2014;31:122-125.
15.
Heinemann L, Franc S, Phillip M, Battelino T, Ampudia-Blasco FJ, Bolinder J, Diem P, Pickup J, Hans Devries J: Reimbursement for continuous glucose monitoring: a European view. J Diabetes Sci Technol 2012;6:1498-502.
16.
Huang ES, O'Grady M, Basu A, Winn A, John P, Lee J, Meltzer D, Kollman C, Laffel L, Tamborlane W, Weinzimer S, Wysocki T; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care 2010;33:1269-1274.
17.
Langendam M, Luijf YM, Hooft L, Devries JH, Mudde AH, Scholten RJ: Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev 2012;1:CD008101.
18.
Floyd B, Chandra P, Hall S, Phillips C, Alema-Mensah E, Strayhorn G, Ofili EO, Umpierrez GE: Comparative analysis of the efficacy of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus. J Diabetes Sci Technol 2012;6:1094-1102.
19.
Pickup JC, Freeman SC, Sutton AJ: Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self-monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011;343:d3805.
20.
Poolsup N, Suksomboon N, Kyaw AM: Systematic review and meta-analysis of the effectiveness of continuous glucose monitoring (CGM) on glucose control in diabetes. Diabetol Metab Syndr 2013;5:39.
21.
Szypowska A, Ramotowska A, Dzygalo K, Golicki D: Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials. Eur J Endocrinol 2012;166:567-574.
22.
Wojciechowski P, Ryś P, Lipowska A, Gawęska M, Małecki MT: Efficacy and safety comparison of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes: systematic review and meta-analysis. Pol Arch Med Wewn 2011;121:333-343.
23.
Mauras N, Fox L, Englert K, Beck RW: Continuous glucose monitoring in type 1 diabetes. Endocrine 2013;43:41-50.
24.
Battelino T, Phillip M: Real-time continuous glucose monitoring in randomized control trials. Pediatr Endocrinol Rev 2010;7(suppl 3):401-404.
25.
Hermanides J, Phillip M, DeVries JH: Current application of continuous glucose monitoring in the treatment of diabetes: pros and cons. Diabetes Care 2011;34(suppl 2):S197-S201.
26.
Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M: Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006;29:2730-2732.
27.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-1476.
28.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Beck RW, Buckingham B, Miller K, Wolpert H, Xing D, Block JM, Chase HP, Hirsch I, Kollman C, Laffel L, Lawrence JM, Milaszewski K, Ruedy KJ, Tamborlane WV: Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care 2009;32:1947-1953.
29.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, Chase P, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Huang ES, Kollman C, Kowalski AJ, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer SA, Wilson DM, Wolpert H, Wysocki T, Xing D: The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32:1378-1383.
30.
Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, Jeandidier N, Nicolino M: Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care 2009;32:2245-2250.
31.
O'Connell MA, Donath S, O'Neal DN, Colman PG, Ambler GR, Jones TW, Davis EA, Cameron FJ: Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 2009;52:1250-1257.
32.
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group: Effectiveness of Sensor-Augmented Insulin Pump Therapy in Type 1 Diabetes. N Engl J Med 2010;363:311-320.
33.
Kordonouri O, Pankowska E, Rami B, Kapellen T, Coutant R, Hartmann R, Lange K, Knip M, Danne T: Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 2010;53:2487-2495.
34.
Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J: Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011;34:1-6.
35.
Battelino T, Conget I, Olsen B, Schütz-Fuhrmann I, Hommel E, Hoogma R, Schierloh U, Sulli N, Bolinder J; SWITCH Study Group: The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55:3155-3162.
36.
Mauras N, Beck R, Xing D, Ruedy K, Buckingham B, Tansey M, White NH, Weinzimer SA, Tamborlane W, Kollman C: A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years. Diabetes Care 2012;35:204-210.
37.
Riveline JP, Schaepelynck P, Chaillous L, Renard E, Sola-Gazagnes A, Penfornis A, Tubiana-Rufi N, Sulmont V, Catargi B, Lukas C, Radermecker RP, Thivolet C, Moreau F, Benhamou PY, Guerci B, Leguerrier AM, Millot L, Sachon C, Charpentier G, Hanaire H; EVADIAC Sensor Study Group: Assessment of patient-led or physician-driven continuous glucose monitoring in patients with poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study. Diabetes Care 2012;35:965-971.
38.
Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW: Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs. standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013;310:1240-1247.
39.
Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ, Welsh JB, Lee SW, Kaufman FR; ASPIRE In-Home Study Group: Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224-232.
40.
Maahs DM, Calhoun P, Buckingham BA, Chase HP, Hramiak I, Lum J, Cameron F, Bequette BW, Aye T, Paul T, Slover R, Wadwa RP, Wilson DM, Kollman C, Beck RW; In Home Closed Loop Study Group: A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care 2014;37:1885-1891.
41.
Nørgaard K, Scaramuzza A, Bratina N, Lalić NM, Jarosz-Chobot P, Kocsis G, Jasinskiene E, De Block C, Carrette O, Castañeda J, Cohen O; Interpret Study Group: Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study. Diabetes Technol Ther 2013;15:273-280.
42.
Tansey M, Laffel L, Cheng J, Beck R, Coffey J, Huang E, Kollman C, Lawrence J, Lee J, Ruedy K, Tamborlane W, Wysocki T, Xing D; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Satisfaction with continuous glucose monitoring in adults and youths with type 1 diabetes. Diabet Med 2011;28:1118-1122.
43.
Peyrot M1, Rubin RR; STAR 3 Study Group: Treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial. Diabet Med 2013;30:464-467.
44.
Kordonouri O, Hartmann R, Pankowska E, Rami B, Kapellen T, Coutant R, Lange K, Danne T: Sensor augmented pump therapy from onset of type 1 diabetes: late follow-up results of the Pediatric Onset Study. Pediatr Diabetes 2012;13:515-518.
45.
Bratina N, Battelino T: Insulin pumps and continuous glucose monitoring (CGM) in preschool and school-age children: how schools can integrate technology. Pediatr Endocrinol Rev 2010;7(suppl. 3):417-421.
46.
Drobnic Radobuljac M, Bratina N, Tomori M, Battelino T: Type 1 diabetes and psychosocial risk factors in adolescence. Zdrav Vestn 2012;81:664-675.
47.
Phillip M, Battelino T, Atlas E, Kordonouri O, Bratina N, Miller S, Biester T, Stefanija MA, Muller I, Nimri R, Danne T: Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013;368:824-833.
48.
Nimri R, Danne T, Kordonouri O, Atlas E, Bratina N, Biester T, Avbelj M, Miller S, Muller I, Phillip M, Battelino T: The ‘Glucositter' overnight automated closed loop system for type 1 diabetes: a randomized cross-over trial. Pediatr Diabetes 2013;14:159-167.
49.
Nimri R, Muller I, Atlas E, Miller S, Kordonouri O, Bratina N, Tsioli C, Stefanija MA, Danne T, Battelino T, Phillip M: Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized cross-over trial - interim analysis. Pediatr Diabetes 2014;15:91-99.
50.
Sherr JL, Cengiz E, Palerm CC, Clark B, Kurtz N, Roy A, Carria L, Cantwell M, Tamborlane WV, Weinzimer SA: Reduced hypoglycemia and increased time in target using closed-loop insulin delivery during nights with or without antecedent afternoon exercise in type 1 diabetes. Diabetes Care 2013;36:2909-2914.
51.
Hovorka R, Elleri D, Thabit H, Allen JM, Leelarathna L, El-Khairi R, Kumareswaran K, Caldwell K, Calhoun P, Kollman C, Murphy HR, Acerini CL, Wilinska ME, Nodale M, Dunger DB: Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 2014;37:1204-1211.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.